ClinicalTrials.gg
CompletedNCT04740827ELEVATEUpdated Sep 21, 2023Results posted

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

A Phase 3 interventional study of Atogepant 60 mg and Placebo in Episodic Migraine, sponsored by Allergan. Completed at 114 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
14th of 21
315 · median 468
Started
2021
with 3 others
Phase 3
15 of 21
3 open now
Registered
8th of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 14th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 8th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.

03

Conditions studied

  • Episodic Migraine

Browse trials for

Keywords

  • Episodic migraine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3, 2018.
  • Age of the participant at the time of migraine onset \< 50 years -History of 4 to 14 migraine days per month on average in the 3 months prior to Visit 1 in the investigator's judgment
  • Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.
  • 4 to 14 migraine days in the 28-day baseline period per eDiary
  • Failed oral migraine prophylaxis medications from 2 to 4 medication classes

Exclusion criteria

Exclusion Criteria:

  • Any hematologic, endocrine, pulmonary, hepatic, gastrointestinal, or neurologic disease
  • Participant has any other concurrent pain condition that, in the opinion of the investigator, may significantly impact the current headache disorder
  • In the opinion of the investigator, confounding psychiatric conditions, dementia, epilepsy, or significant neurological disorders other than migraine
  • Has ≥ 15 headache days per month on average across the 3 months prior to Visit 1 in the investigator's judgment
  • Has ≥ 15 headache days in the 28-day baseline period per eDiary
  • Clinically significant cardiovascular or cerebrovascular disease
  • Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018
  • Has a current diagnosis of chronic migraine, new persistent daily headache, medication overuse headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3, 2018
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
315 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received atogepant-matching placebo tablets, orally, once daily (QD) for up to 12 weeks in a double-blind (DB) treatment period.

    Drug: Placebo

  • Active comparator
    Atogepant 60 mg

    Participants received atogepant 60 mg, orally, QD for up to 12 weeks in a DB treatment period.

    Drug: Atogepant 60 mg

Interventions

  • Atogepant tablets.

  • DrugPlacebo

    Atogepant matching placebo tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline to Week 12

  2. Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in OTHE Population

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. MMRM was used for analysis.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Number of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in mITT Population

    Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50% reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days are equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28.

    Time frame: Baseline to Week 12

  2. Number of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in OTHE Population

    Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50% reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days are equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28.

    Time frame: Baseline to Week 12

  3. Change From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in mITT Population

    Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. MMRM was used for analysis.

    Time frame: Baseline to Week 12

  4. Change From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in OTHE Population

    Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. MMRM was used for analysis.

    Time frame: Baseline to Week 12

  5. Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in mITT Population

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 12

  6. Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in OTHE Population

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 12

  7. Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in mITT Population

    The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. MMRM was used for analysis.

    Time frame: Baseline to Week 12

  8. Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in OTHE Population

    The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. MMRM was used for analysis.

    Time frame: Baseline to Week 12

  9. Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D) Across the 12-Week Treatment Period in mITT Population

    The AIM-D is a 11-item patient-reported outcome (PRO) measure that assesses the impact of migraine on the performance of daily activities which include, 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden).

    Time frame: Baseline to Week 12

  10. Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across the 12-Week Treatment Period in mITT Population

    The AIM-D is a 11-item PRO measure that assesses the impact of migraine on the performance of daily activities which includes 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden).

    Time frame: Baseline to Week 12

  11. Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in OTHE Population

    HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant's ability to function. Responses are based on frequency using a 5-point scale ranging from "never" to "always." The HIT-6 total score, which ranges from 36 to 78, is the sum of the responses - each of which is assigned a score ranging from 6 points (never) to 13 points (always). MMRM was used for the analyses.

    Time frame: Baseline to Week 12

  12. Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. TEAEs were defined as any AE with the onset that was after the first dose of study intervention.

    Time frame: From first dose of study drug until 30 days after last dose of study drug (up to Week 12)

07

Results

Posted Sep 21, 2023

Participant flow

Double-blind Treatment (Up to Week 12)
Participant flow — Double-blind Treatment (Up to Week 12)
MilestonePlaceboAtogepant 60 mg
Started158157
Safety population157156
Modified intent-to-treat (mitt) population154151
Off-treatment hypothetical estimand (othe) population155154
Completed151144
Not completed713
Withdrew: Adverse event24
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject22
Withdrew: Pregnancy01
Withdrew: Protocol deviation35
Follow-up Period (Week 13 to Week 16)
Participant flow — Follow-up Period (Week 13 to Week 16)
MilestonePlaceboAtogepant 60 mg
Started4344
Completed4244
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryChange From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · migraine days per month
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population
migraine days per monthPlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population-1.86 ± 0.389-4.29 ± 0.397
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -2.43 · 95% CI -3.27 to -1.59MMRM=baseline monthly migraine days as covariate, treatment group, visit, region and number of classes of failed prior treatments as fixed factors; treatment group and baseline-by-visit as interaction terms, with an unstructured covariance matrix.
PrimaryChange From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in OTHE Population

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. MMRM was used for analysis.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · migraine days per month
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in OTHE Population
migraine days per monthPlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in OTHE Population-1.85 ± 0.388-4.20 ± 0.393
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -2.35 · 95% CI -3.19 to -1.52MMRM=baseline monthly migraine days as covariate, treatment group, visit, region and number of classes of failed prior treatments as fixed factors; treatment group and baseline-by-visit as interaction terms, with an unstructured covariance matrix.
SecondaryNumber of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in mITT Population

Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50% reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days are equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in mITT Population
ParticipantsPlaceboAtogepant 60 mg
Number of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in mITT Population2777
Statistical analysis
  • Placebo vs Atogepant 60 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.15 · 95% CI 3.02 to 8.79Odds ratio and p-value are based on logistic regression with treatment group, region, baseline monthly migraine days, and number of classes of failed prior prophylactic treatments (2 and \>2) as explanatory variables.
SecondaryNumber of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in OTHE Population

Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50% reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days are equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in OTHE Population
ParticipantsPlaceboAtogepant 60 mg
Number of Participants With At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days Across the 12-week Treatment Period in OTHE Population2878
Statistical analysis
  • Placebo vs Atogepant 60 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.82 · 95% CI 2.85 to 8.14Odds ratio and p-value are based on logistic regression with treatment group, region, baseline monthly migraine days, and number of classes of failed prior prophylactic treatments (2 and \>2) as explanatory variables.
SecondaryChange From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in mITT Population

Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. MMRM was used for analysis.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · headache days per month
Change From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in mITT Population
headache days per monthPlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in mITT Population-1.93 ± 0.424-4.21 ± 0.431
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -2.28 · 95% CI -3.15 to -1.42MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in OTHE Population

Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. MMRM was used for analysis.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · headache days per month
Change From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in OTHE Population
headache days per monthPlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Headache Days Across the 12-week Treatment Period in OTHE Population-1.91 ± 0.423-4.10 ± 0.429
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -2.19 · 95% CI -3.05 to -1.32MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in mITT Population

An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in mITT Population
acute medication use days per monthPlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in mITT Population-1.11 ± 0.359-3.79 ± 0.363
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -2.68 · 95% CI -3.43 to -1.93MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in OTHE Population

An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in OTHE Population
acute medication use days per monthPlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-week Treatment Period in OTHE Population-1.10 ± 0.358-3.70 ± 0.361
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -2.61 · 95% CI -3.36 to -1.86MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in mITT Population

The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. MMRM was used for analysis.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in mITT Population
score on a scalePlaceboAtogepant 60 mg
Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in mITT Population15.41 ± 2.07833.09 ± 2.102
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: 17.67 · 95% CI 13.05 to 22.30MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in OTHE Population

The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. MMRM was used for analysis.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in OTHE Population
score on a scalePlaceboAtogepant 60 mg
Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ) v2.1 Role Function-Restrictive Domain Score at Week 12 in OTHE Population15.38 ± 2.04733.26 ± 2.065
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: 17.88 · 95% CI 13.34 to 22.42MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D) Across the 12-Week Treatment Period in mITT Population

The AIM-D is a 11-item patient-reported outcome (PRO) measure that assesses the impact of migraine on the performance of daily activities which include, 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden).

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D) Across the 12-Week Treatment Period in mITT Population
score on a scalePlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D) Across the 12-Week Treatment Period in mITT Population-4.97 ± 0.800-9.68 ± 0.826
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -4.71 · 95% CI -6.37 to -3.05MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across the 12-Week Treatment Period in mITT Population

The AIM-D is a 11-item PRO measure that assesses the impact of migraine on the performance of daily activities which includes 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden).

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across the 12-Week Treatment Period in mITT Population
score on a scalePlaceboAtogepant 60 mg
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across the 12-Week Treatment Period in mITT Population-3.03 ± 0.748-7.43 ± 0.773
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -4.39 · 95% CI -5.94 to -2.85MMRM=baseline as covariate, treatment group, visit, region, number of classes of failed prior treatments, number of migraine days during baseline period as fixed factors; treatment group and baseline-by-visit with an unstructured covariance matrix.
SecondaryChange From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in OTHE Population

HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant's ability to function. Responses are based on frequency using a 5-point scale ranging from "never" to "always." The HIT-6 total score, which ranges from 36 to 78, is the sum of the responses - each of which is assigned a score ranging from 6 points (never) to 13 points (always). MMRM was used for the analyses.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in OTHE Population
score on a scalePlaceboAtogepant 60 mg
Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in OTHE Population-4.14 ± 0.795-10.56 ± 0.804
Statistical analysis
  • Placebo vs Atogepant 60 mg · MMRM · p = <0.0001 · Least squares mean difference: -6.42 · 95% CI -8.22 to -4.63MMRM=baseline monthly migraine days as covariate, treatment group, visit, region and number of classes of failed prior treatments as fixed factors; treatment group and baseline-by-visit as interaction terms, with an unstructured covariance matrix.
SecondaryNumber of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. TEAEs were defined as any AE with the onset that was after the first dose of study intervention.

Time frame:
From first dose of study drug until 30 days after last dose of study drug (up to Week 12)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboAtogepant 60 mg
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)8481

Adverse events

Collected over All cause mortality is reported from enrollment to end of study; median time on follow up was 93.5 and 90.0 days for Placebo and Atogepant, respectively. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean duration on study drug was 83.7 days and 81.7 days for Placebo and Atogepant, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/158 (0%)0/157 (0%)34/157 (21.7%)
Atogepant 60 mg0/157 (0%)4/156 (2.6%)40/156 (25.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboAtogepant 60 mg
VENTRICULAR TACHYCARDIACardiac disorders0/1571/156
BREAST CANCER STAGE IINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1571/156
INVASIVE BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1571/156
ABORTION INDUCEDSurgical and medical procedures0/1571/156
Most frequent other events
Most frequent other events
EventPlaceboAtogepant 60 mg
CONSTIPATIONGastrointestinal disorders4/15716/156
COVID-19Infections and infestations15/15713/156
NASOPHARYNGITISInfections and infestations12/1578/156
NAUSEAGastrointestinal disorders5/15711/156

Baseline characteristics

Intent-to-Treat (ITT) Population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboAtogepant 60 mgTotal
Mean43.5 ± 10.2940.8 ± 10.7142.1 ± 10.56
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtogepant 60 mgTotal
Female141140281
Male171734
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAtogepant 60 mgTotal
Hispanic or Latino4711
Not Hispanic or Latino154150304
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAtogepant 60 mgTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American437
White152150302
More than one race022
Unknown or Not Reported000
Monthly Migraine Days in mITT Population
Monthly Migraine Days in mITT Population(Migraine days per month)PlaceboAtogepant 60 mgTotal
Mean9.3 ± 2.419.0 ± 2.309.2 ± 2.35
Monthly Migraine Days in OTHE Population
Monthly Migraine Days in OTHE Population(Migraine days per month)PlaceboAtogepant 60 mgTotal
Mean9.3 ± 2.409.1 ± 2.299.2 ± 2.34
08

Study locations

114 sites
  • Axiom Research /ID# 226379
    Colton, California 92324, United States
  • Pharmacology Research Institute (PRI) - Encino (Wake) /ID# 226434
    Encino, California 91316, United States
  • Pharmacology Research Institute (PRI) - Los Alamitos (Wake) /ID# 226388
    Los Alamitos, California 90720-3500, United States
  • Pharmacology Research Institute (PRI) - Los Alamitos (Wake) /ID# 226405
    Los Alamitos, California 90720-3500, United States
  • Excell Research, Inc /ID# 228386
    Oceanside, California 92056, United States
  • Alpine Clinical Research Center /ID# 226201
    Boulder, Colorado 80301-1880, United States
  • Sensible Healthcare /ID# 226197
    Ocoee, Florida 34761, United States
  • Meridien Research /ID# 226224
    Saint Petersburg, Florida 33709, United States
  • Meridien Research /ID# 226302
    Saint Petersburg, Florida 33709, United States
  • Velocity Clinical Research - Boise /ID# 226320
    Meridian, Idaho 83642, United States
  • Allied Physicians - Fort Wayne Neurological Center /ID# 226350
    Fort Wayne, Indiana 46804, United States
  • Deaconess Clinic - Gateway Health Center /ID# 226481
    Newburgh, Indiana 47630, United States
  • Pharmasite Research, Inc. /ID# 226445
    Baltimore, Maryland 21208, United States
  • StudyMetrix Research /ID# 226297
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC /ID# 226273
    Springfield, Missouri 65807, United States
  • Methodist Physicians Clinic /ID# 226470
    Fremont, Nebraska 68025, United States
  • Amici Clinical Research - Raritan /ID# 226282
    Raritan, New Jersey 08869, United States
  • Albuquerque Clinical Trials, Inc /ID# 233445
    Albuquerque, New Mexico 87102, United States
  • CTI Clinical Trial and Consulting /ID# 226281
    Cincinnati, Ohio 45212, United States
  • FutureSearch Trials of Neurology /ID# 226423
    Austin, Texas 78731, United States
  • Austin Clinical Trial Partners /ID# 228387
    Austin, Texas 78737, United States
  • DiscoveResearch, Inc /ID# 226491
    Bryan, Texas 77802, United States
  • FutureSearch Trials of Dallas, LP /ID# 226493
    Dallas, Texas 75231, United States
  • LinQ Research, LLC /ID# 226227
    Pearland, Texas 77584, United States
  • Highland Clinical Research /ID# 226288
    Salt Lake City, Utah 84124, United States
  • Northwest Clinical Research Center /ID# 226228
    Bellevue, Washington 98007, United States
  • Alfred Health /ID# 226341
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital /ID# 226402
    Parkville, Victoria 3050, Australia
  • Aggarwal and Associates Limited /ID# 226321
    Brampton, Ontario L6T 0G1, Canada
  • Ottawa Headache Centre Research Inc /ID# 226257
    Ottawa, Ontario K2G 6E2, Canada
  • Diex Recherche Sherbrooke Inc. /ID# 226375
    Sherbrooke, Quebec J1L 0H8, Canada
  • POLIKLINIKA CHOCEN, a.s. /ID# 226510
    Chocen, 565 01, Czechia
  • BRAIN-SOULTHERAPY s.r.o. /ID# 226489
    Kladno, 272 01, Czechia
  • CCR Ostrava, s.r.o. /ID# 226279
    Ostrava, 702 00, Czechia
  • A-SHINE s.r.o. /ID# 226208
    Plzen, 301 00, Czechia
  • CLINTRIAL s.r.o. /ID# 226192
    Prague 10, 100 00, Czechia
  • CCR Czech a.s /ID# 226270
    Prague 4, 140 00, Czechia
  • FORBELI s.r.o. /ID# 226396
    Prague, 160 00, Czechia
  • DADO MEDICAL s.r.o. /ID# 226548
    Praha, 120 00, Czechia
  • CCR Prague s.r.o. /ID# 226214
    Praha, 130 00, Czechia
  • INEP medical s.r.o. /ID# 226531
    Praha, 186 00, Czechia
  • Vestra Clinics s.r.o. /ID# 226547
    Rychnov nad Kneznou, 516 01, Czechia
  • NeuroMed Zlin s.r.o. /ID# 226487
    Zlin, 760 01, Czechia
  • Rigshospitalet Glostrup /ID# 226271
    Glostrup, Hovedstaden 2600, Denmark
  • CHU Nice - Hopital de Cimiez /ID# 226401
    Nice, Alpes-Maritimes 06000, France
  • CHU de SAINT ETIENNE - Hopital Nord /ID# 226397
    St. Priest En Jarez, Loire 42270, France
  • CHU Lille /ID# 226501
    Lille, Nord 59000, France
  • CHU Clermont Ferand - Hopital Gabriel Montpied /ID# 226438
    Clermont Ferrand, 63000, France
  • AP-HP - Hopital Lariboisière /ID# 226221
    Paris, 75010, France
  • Universitaetsklinikum Tuebingen /ID# 226529
    Tubingen, Baden-Wuerttemberg 72076, Germany
  • Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 226441
    Berlin, 10117, Germany
  • Klinische Forschung Dresden GmbH /ID# 226194
    Dresden, 01069, Germany
  • Praxis Dr. Gendolla /ID# 226497
    Essen, 45133, Germany
  • Universitaetsklinikum Essen /ID# 226527
    Essen, 45147, Germany
  • Klinische Forschung Hannover-Mitte GmbH /ID# 226195
    Hannover, 30159, Germany
  • Universitaetsklinikum Jena Klinik fuer Neurologie /ID# 226439
    Jena, 07747, Germany
  • Vitos Orthopaedische Klinik Kassel gemeinnuetzige GmbH /ID# 231767
    Kassel, 34131, Germany
  • Schmerzklinik Kiel /ID# 226499
    Kiel, 24149, Germany
  • AmBeNet GmbH /ID# 226213
    Leipzig, 04107, Germany
  • Pharmakologisches Studienzentrum Chemnitz GmbH /ID# 226202
    Mittweida, 09648, Germany
  • Universitaetsmedizin Rostock /ID# 226517
    Rostock, 18057, Germany
  • Neuropoint GmbH /ID# 226377
    Ulm, 89073, Germany
  • Neuropraxis Muenchen Sued /ID# 226216
    Unterhaching, 82008, Germany
  • Studienzentrum Nord-West /ID# 226360
    Westerstede, 26655, Germany
  • Intermed GmbH /ID# 226376
    Wiesbaden, 65189, Germany
  • DKD Helios Klinik Wiesbaden /ID# 226534
    Wiesbaden, 65191, Germany
  • Bugat Pal Korhaz /ID# 226357
    Gyöngyös, Heves 3200, Hungary
  • Valeomed Kft /ID# 226535
    Esztergom, Komarom-Esztergom 2500, Hungary
  • Szent Borbala Korhaz /ID# 226400
    Tatabanya, Komarom-Esztergom 2800, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 226485
    Kaposvár, Somogy 7400, Hungary
  • Mind Klinika Kft. /ID# 233438
    Budapest, 1024, Hungary
  • Clinexpert Kft /ID# 226467
    Budapest, 1033, Hungary
  • Department of Neurology, University of Szeged /ID# 226442
    Szeged, 6725, Hungary
  • Ospedale Ss. Filippo e Nicola /ID# 226530
    Avezzano, L Aquila 67051, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico di Roma /ID# 226361
    Rome, Lazio 00128, Italy
  • Univ. of Bologna-IRCCS-Istituto delle Scienze Neurologiche /ID# 226475
    Bologna, 40126, Italy
  • Azienda Ospedaliero Universitaria Careggi /ID# 226502
    Florence, 50134, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 226399
    Milan, 20133, Italy
  • AOU Universita degli Studi della Campania Luigi Vanvitelli /ID# 226503
    Napoli, 80138, Italy
  • Universita di Pavia /ID# 226536
    Pavia, 27100, Italy
  • Martini Ziekenhuis /ID# 226343
    Groningen, 9728 NT, Netherlands
  • Canisius-Wilhelmina Ziekenhuis /ID# 226488
    Nijmegen, 6532 SZ, Netherlands
  • ZorgSaam Zorggroep Zeeuws-Vlaanderen /ID# 226317
    Terneuzen, 4535 PA, Netherlands
  • Centrum Medyczne Oporow /ID# 226469
    Wroclaw, Dolnoslaskie 52-416, Poland
  • NZOZ Vitamed /ID# 226293
    Bydgoszcz, Kujawsko-pomorskie 85-079, Poland
  • Gabinet Lekarski Jacek Rozniecki /ID# 226323
    Lodz, Lodzkie 90-338, Poland
  • Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 226235
    Lublin, Lubelskie 20-582, Poland
  • Specjalistyczne Gabinety Sp. z o.o. /ID# 226266
    Krakow, Malopolskie 30-539, Poland
  • Centrum Leczenia Padaczki i Migreny /ID# 226543
    Krakow, Malopolskie 31-209, Poland
  • Duplicate_RCMed Oddzial Sochaczew /ID# 226369
    Sochaczew, Mazowieckie 96-500, Poland
  • Centrum Medyczne Pratia Gdynia /ID# 226437
    Gdynia, Pomorskie 81-338, Poland
  • Silmedic Sp. z o.o. /ID# 226267
    Katowice, Slaskie 40-282, Poland
  • Solumed Centrum Medyczne /ID# 226299
    Poznan, Wielkopolskie 60-529, Poland
  • EuroMedis sp. z o.o. /ID# 226268
    Szczecin, Zachodniopomorskie 70-111, Poland
  • Bashkir State Medical University /ID# 226552
    Ufa, Bashkortostan, Respublika 450005, Russian Federation
  • Kazan State Medical University /ID# 226498
    Kazan, Tatarstan, Respublika 420012, Russian Federation
  • Sbhi Cp 2 Hdm /Id# 226494
    Moscow, 117556, Russian Federation
  • University Headache Clinic /ID# 226435
    Moscow, 119221, Russian Federation
  • Cephalgolog /ID# 226541
    Moscow, 125040, Russian Federation
  • Hospital Unversitario Marques de Valdecilla /ID# 226239
    Santander, Cantabria 39008, Spain

Showing the first 100 of 114 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2022, 16 months.

Results were first posted in Sep 2023, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 5, 2021
StartActual
Mar 5, 2021
Primary completionActual
Aug 4, 2022
CompletionActual
Aug 4, 2022
Results first posted
Sep 21, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04740827
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Mar 5, 2021
Primary completion
Aug 4, 2022
Completion
Aug 4, 2022
Results posted
Sep 21, 2023
Last update
Sep 21, 2023

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion